Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies
Eman A. Abd El‐Meguid, Ahmed M. Naglah, Gaber O. Moustafa, Hanem M. Awad, Ahmed M. El Kerdawy
Topics & Concepts
ChemistryBenzothiazoleIC50SorafenibErlotinibStereochemistryDoxorubicinCytotoxicityDocking (animal)Cell cultureQuantitative structure–activity relationshipPharmacologyIn vitroBiochemistryEpidermal growth factor receptorReceptorCancer researchHepatocellular carcinomaBiologyNursingGeneticsSurgeryMedicineChemotherapySynthesis and biological activityHER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations